1. Introduction {#sec1}
===============

Obesity and associated health complications afflict millions of people worldwide. Growth differentiation factor 15 (GDF15) has emerged as a potential anti-obesity agent. It circulates as a 25-kDa homodimer and is a member of the transforming growth factor- β (TGF-β) super family. Originally identified in 1997 as a factor that inhibits macrophage activation [@bib1], a role for GDF15 in the regulation of energy balance was established in 2007, when it was demonstrated that GDF15 suppresses food intake [@bib2]. Subsequent pharmacological and genetic studies confirmed that GDF15 administration lowers body weight, largely by decreasing appetite [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]. Some studies have also suggested that GDF15 can directly increase thermogenesis and improve insulin sensitivity [@bib8], [@bib9], [@bib10]. Recently, the GDNF family receptor α-like (GFRAL), located in the area postrema of the hindbrain, was identified as the receptor that mediates the anorexic effects of GDF15 [@bib4], [@bib5], [@bib6], [@bib7].

GDF15 is expressed in most tissues [@bib11] including skeletal muscle [@bib12], and its abundance generally increases in response to cellular stress or injury. For example, circulating GDF15 levels are elevated in patients with cancer or following myocardial injury (reviewed in [@bib13], [@bib14]). In mouse skeletal muscle, GDF15 expression markedly increases in response to mitochondrial stress [@bib8], [@bib15], which can lead to increased plasma GDF15 levels [@bib8]. In humans, circulating GDF15 levels are elevated in patients with muscle atrophy [@bib12] and in patients with mitochondrial myopathy [@bib16]. These data suggest that in response to a stress stimulus, skeletal muscle could release GDF15 into the circulation in humans.

A bout of exercise represents a transient physiological stress [@bib17] that affects overall energy metabolism by increasing energy expenditure [@bib17], improving insulin sensitivity [@bib18], and altering food preference and food intake patterns [@bib19]. During exercise, the contracting skeletal muscle is challenged by energy (e.g. ADP to ATP ratio), mechanical (e.g. stretch) and chemical (e.g. reactive oxygen species) stress. In addition, metformin has been shown to increase serum GDF15 levels in humans [@bib20]. Both metformin and exercise activate the energy sensor AMP-activated protein kinase (AMPK) in skeletal muscle [@bib21], [@bib22]. We therefore tested the hypothesis that exercise increases circulating GDF15 level in humans, by triggering GDF15 release from skeletal muscle.

2. Material and methods {#sec2}
=======================

2.1. Subjects and diet {#sec2.1}
----------------------

Seven men were recruited for the study, which was approved by the Copenhagen Ethics Committee (Reg. number H-16040740) and performed in accordance with the Declaration of Helsinki. Informed written consent was received from each participant prior to study inclusion. All subjects were healthy, moderately physically active, and with no family history of diabetes. The subjects were 27 ± 1.0 (means ± SEM) years old, with a body weight of 85 ± 3.6 kg, body mass index (BMI) of 24 ± 0.7 kg/m^2^ and maximal oxygen uptake (VO~2~ peak) of 50 ± 1.2 ml/kg/min.

Maximal oxygen uptake was measured by an incremental exercise test on a Monark Ergomedic 839E bicycle ergometer (Monark, Sweden).

Subjects were studied twice, at least two weeks apart, in a randomized order. One trial was an exercise trial and the other a rest trial. Before each trial subjects consumed a eucaloric controlled diet for 3 days to ensure the same conditions before each trial. The daily energy requirements were individually determined from weighed dietary registrations and predicted equations from WHO/FAO/UNU. All food items were weighed and prepared in the metabolic kitchen and menus were delivered to the subjects and ingested at home. The diet consisted of 60 energy-percent (E%) carbohydrate, 25E% fat, and 15E% protein.

2.2. Experimental protocol {#sec2.2}
--------------------------

After three days on the control diet, subjects ingested a light standardized breakfast (1.6 MJ) at 6 A.M at home. Subjects arrived at the institute at 8 A.M, and after 10--15 min of supine rest, teflon catheters were inserted into the femoral artery and vein under local anesthesia. After continued supine rest, basal blood samples were obtained from the femoral artery and vein at 10 A.M (0 min). For the exercise trial, subjects then initiated a 60 min exercise bout on the Monark Ergomedic 839E bicycle ergometer at 67 ± 1% of maximal oxygen uptake (VO~2max~). Femoral arterial and femoral venous samples were collected simultaneously during exercise at 20, 40, and 60 min and again after 10 and 120 min of resting supine recovery without food intake. For the rest trial, subjects remained in the supine position for 4 h. Arterial blood was collected at 10 A.M. (0 min) and again after 60 and 180 min of rest matching the time schedule of the exercise trial.

2.3. Analysis {#sec2.3}
-------------

Blood was sampled in heparinized syringes and transferred to EDTA-containing tubes and centrifuged at 4 °C at 3000*g* for 5 min. Plasma was aspirated, frozen, and stored at −80 °C until analysis. GDF15 was measured in plasma using the Quantikine ELISA Human GDF-15 Immunoassay (ELISA, R&D systems, Inc., Minneapolis, USA, catalog number: DGD150). Arterial plasma glucose and blood lactate concentrations and blood hematocrit were measured on an ABL 800 flex (Radiometer Medical, Denmark).

2.4. Statistics {#sec2.4}
---------------

Statistical analyses were performed in SigmaPlot 13.0 (Systat Software, Inc., Germany) or in GraphPad Prism 7 (GraphPad Software, Inc., USA). For the exercise trial, a two-way ANOVA with repeated measurements (RM) was used. The 20 and 40 min time points were excluded in this analysis, because four blood samples could not be analyzed ([Table S1](#appsec1){ref-type="sec"}). Therefore, for the a--v difference data ([Figure 1](#fig1){ref-type="fig"}B) a regular one-way ANOVA was performed to compare differences among the time points. A two-way ANOVA with RM was used for the data from the rest trial. When ANOVA analyses revealed significant differences, the Tukey *post hoc* test was used for multiple comparisons. *p* \< 0.05 was considered statistically significant.Figure 1**Vigorous submaximal exercise increases circulating GDF15 in humans.** Seven healthy males exercised at 67% of their VO~2max~ for 1 h. Blood, sampled from the femoral artery and femoral vein, was drawn before (Pre), during (EX) and after (Recovery) exercise at indicated time points. Plasma GDF15 concentrations were determined in these samples and are shown for each individual subject (A,B) and as means ± SEM (C). The matching symbol in A and B represents the same subject. The arteriovenous (a--v) GDF15 difference was calculated (D). In the same subjects, plasma GDF15 levels were determined in blood from the femoral artery, collected during a separate rest study (E). Delta (Δ) GDF15 levels were calculated for the exercise and rest trial for the indicated time points (F). Data for D--F are also means ± SEM. \**p* \< 0.05, \*\*\**p* \< 0.001 compared to Pre (in C) or as indicated (in F); ^\#\#\#^*p* \< 0.001 compared to 60 min.

3. Results {#sec3}
==========

During the exercise trial, plasma GDF15 levels increased from ∼215 pg/ml at rest to ∼295 pg/ml (*p* \< 0.001) at the end of the exercise bout ([Figure 1](#fig1){ref-type="fig"}A). GDF15 further increased to ∼350 pg/ml (*p* \< 0.001) at the end of the recovery ([Figure 1](#fig1){ref-type="fig"}A). This exercise-induced increase in circulating GDF15 was remarkably consistent, with GDF15 increasing in every subject. At every time-point, GDF15 concentrations between the femoral artery and femoral vein were similar ([Figure 1](#fig1){ref-type="fig"}A--C). In agreement, the arteriovenous (a--v) GDF15 difference was unaffected by exercise and by recovery from exercise ([Figure 1](#fig1){ref-type="fig"}D). Arterial GDF15 plasma levels, measured in the same subjects during the time- and diet-matched rest study, remained unchanged ([Figure 1](#fig1){ref-type="fig"}E). Absolute changes in arterial GDF15 levels were 2.6-fold (*p* \< 0.05) and 16.7-fold (*p* \< 0.001) higher during the exercise trial compared to the rest trial at 60 min (exercise stop) and 180 min (recovery), respectively ([Figure 1](#fig1){ref-type="fig"}F).

Baseline (0 min) respiratory exchange ratio (RER), oxygen uptake, plasma glucose, blood lactate, and hematocrit concentrations were similar in the two trials ([Table 1](#tbl1){ref-type="table"}). Throughout the rest trial, these parameters remained unchanged. During the 60 min-long exercise bout, oxygen uptake, blood lactate, and hematocrit concentrations increased significantly and returned to baseline levels after 2 h of recovery ([Table 1](#tbl1){ref-type="table"}). Heart rate was 167 ± 5 bpm at the end of exercise.Table 1Respiratory exchange ratio (RER) and oxygen uptake (VO~2~), as well as plasma glucose, blood lactate and hematocrit (Hct) concentrations determined in femoral arterial blood sampled at baseline, during 60 min of exercise and subsequent recovery, or during 60 and 180 min of rest.BaselineExercise/restRecovery0 min20 min40 min60 min180 min**RER** EX0.87 ± 0.020.98 ± 0.010.95 ± 0.010.96 ± 0.01††^∗∗^0.85 ± 0.04 REST0.88 ± 0.03----0.88 ± 0.010.89 ± 0.02**VO**~**2**~**(L**⋅**min**^**−**1^**)** EX0.3 ± 0.02.7 ± 0.12.9 ± 0.12.9 ± 0.2†††^∗∗∗^0.3 ± 0.0 REST0.3 ± 0.0----0.3 ± 0.00.3 ± 0.0**Arterial glucose (mmol∙L**^**−**1^**)** EX5.4 ± 0.15.2 ± 0.25.1 ± 0.25.7 ± 0.55.4 ± 0.1 REST5.5 ± 0.1----5.4 ± 0.15.3 ± 0.1**Arterial lactate (mmol∙L**^**−**1^**)** EX0.7 ± 0.03.9 ± 0.53.4 ± 0.44.1 ± 0.5†††^∗∗∗^0.6 ± 0.0 REST0.7 ± 0.1----0.7 ± 0.10.7 ± 0.1**Hct (%)** EX45.1 ± 1.049.3 ± 0.949.5 ± 0.848.8 ± 0.8 †††^∗∗∗^45.0 ± 1.0 REST44.6 ± 1.3----45.0 ± 1.345.0 ± 1.4[^1][^2]

4. Discussion {#sec4}
=============

Our data demonstrate that circulating GDF15 levels increase with an acute bout of vigorous submaximal exercise in humans. Furthermore, we show that this increase does not appear to be mediated by an exercise-induced release of GDF15 from the exercising muscle, because venous and arterial concentrations of GDF15 across the exercised leg were similar. This is the first well-controlled study to measure GDF15 levels during a bout of exercise and in the subsequent recovery period from exercise. A previous study reported higher GDF15 levels in subjects after a 246 km-long ultramarathon race [@bib23]. However, this is an extreme form of exercise that lasts for ∼24--36 h; also, the study lacked crucial time- and diet-matched control groups, which are imperative for interpretation, especially since GDF15 levels exhibit considerable diurnal variation in humans [@bib24]. In addition, the role of skeletal muscle as a potential source of GDF15 has not been previously assessed in humans.

Our finding of an exercise-induced increase in GDF15 levels gives rise to several hypotheses and implications. First, future studies should clarify whether GDF15 is necessary for some of the exercise-associated metabolic benefits. Second, given the anorexic nature of GDF15, it is tempting to speculate that GDF15 is involved in the transient exercise-induced suppression of appetite in humans [@bib25]. Third, GDF15 is being actively considered as a clinical biomarker, for example, to predict cardiac complications [@bib14]. Exercise history should now be accounted for in such applications. Fourth, since skeletal muscle is not the source of the rise in plasma GDF15 during vigorous submaximal exercise, the responsible organ(s) as well as the mechanisms remain to be identified in humans. It remains possible that GDF15 is secreted from muscle to act locally in an autocrine or paracrine manner, but, notably, *Gfral* expression was not detected in peripheral tissues, including skeletal muscle, in the mouse [@bib4].

Our findings also have limitations. For now, they apply to young, relatively fit, male subjects. Factors such as sex, age, exercise intensity, the type of exercise, and initial fitness level will have to be considered in future studies. In addition, a minor part of the increase in plasma GDF15 during exercise can likely be attributed to an exercise-induced hemoconcentration, since we detected a rise in hematocrit concentration of 8--9% during exercise. During recovery, however, hematocrit levels returned to baseline and therefore, hemoconcentration does not contribute to the marked increase in circulating GDF15 2 h after the exercise bout.

5. Conclusion {#sec5}
=============

We have identified exercise as a disease-unrelated, physiological stimulus that increases endogenous circulating GDF15 levels in humans. This exercise effect appears to occur without direct contribution from skeletal muscle.
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[^1]: Data are expressed as means ± SEM. ††*p* \< 0.01, †††*p* \< 0.001 different from baseline and recovery values. \*\**p* \< 0.01, \*\*\**p* \< 0.001 different from REST at the same time point.

[^2]: 20 and 40 min values were excluded from statistical analysis because values at these time points were not obtained in the rest trial.
